Valuation: Ipsen

Market Cap 12.18B 13.64B 11.32B 10.29B 19.37B 1,292B 19.71B 136B 53.18B 674B 51.19B 50.1B 2,157B P/E 2026 *
12.4x
P/E 2027 * 12.3x
Enterprise Value 10.92B 12.23B 10.15B 9.23B 17.37B 1,159B 17.68B 122B 47.69B 604B 45.9B 44.93B 1,934B EV / Sales 2026 *
2.38x
EV / Sales 2027 * 2.13x
Free-Float
40.65%
Yield 2026 *
1.03%
Yield 2027 * 1.05%
1 day+1.46%
1 week+3.59%
Current month+3.15%
1 month-7.77%
3 months-7.83%
6 months-9.58%
Current year+24.01%
1 week 141.8
Extreme 141.8
147.4
1 month 138.5
Extreme 138.5
158.5
Current year 116.5
Extreme 116.5
172.7
1 year 113.2
Extreme 113.2
172.7
3 years 90.2
Extreme 90.2
172.7
5 years 77.76
Extreme 77.76
172.7
10 years 36.84
Extreme 36.84
172.7
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2020
Chief Executive Officer 57 31/12/2019
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 29/08/2005
Chairman 68 21/11/2010
Director/Board Member 69 31/05/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.46%+3.59% - - 13.64B
+3.55%+7.01%+51.42%+105.45% 1,116B
-0.25%-1.25%+32.49%+61.48% 610B
-0.03%+4.03%+25.28%+91.54% 501B
-1.48%+1.97%+72.62%+39.59% 358B
-0.83%+5.51%+32.32%+49.71% 366B
-1.08%+4.67%+19.47%+42.96% 288B
-1.61%+4.03%-0.57%+13.76% 261B
+1.86%+6.53%+45.98%+52.77% 235B
+2.49%+6.98%+33.03%+102.67% 195B
Average +0.41%+5.27%+34.67%+62.21% 436.64B
Weighted average by Cap. +0.81%+4.93%+38.27%+71.70%

Financials

2026 *2027 *
Net sales 4.59B 5.14B 4.26B 3.88B 7.29B 487B 7.43B 51.2B 20.03B 254B 19.28B 18.87B 812B 4.71B 5.28B 4.38B 3.98B 7.5B 500B 7.63B 52.62B 20.59B 261B 19.82B 19.4B 835B
Net income 1.01B 1.13B 937M 853M 1.6B 107B 1.63B 11.26B 4.4B 55.83B 4.24B 4.15B 179B 1.02B 1.15B 951M 865M 1.63B 109B 1.66B 11.43B 4.47B 56.67B 4.3B 4.21B 181B
Net Debt -1.26B -1.41B -1.17B -1.06B -2B -133B -2.04B -14.03B -5.49B -69.59B -5.28B -5.17B -223B -2.15B -2.41B -2B -1.82B -3.42B -228B -3.48B -23.97B -9.38B -119B -9.03B -8.84B -380B
Projected Income Statement - Annual - Ipsen
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
16/10/26 €147.20 -0.14%
15/10/26 €147.40 +3.95%
14/10/26 €141.80 -1.87%
13/10/26 €144.50 +0.98%
12/10/26 €143.10 +0.70%
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Ipsen
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
148.50EUR
Average target price
164.29EUR
Spread / Average Target
+10.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen